ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,949.91
1.83%
US Tech 100
20,724.40
0.27%
Dow Jones
43,221.55
1.65%
Brent Oil
81.09
-0.72%
Bitcoin
99,123.43
-1.39%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) News

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNDX
DateTimeSourceHeadlineSymbolCompany
01/15/20255:34PMPR Newswire (US)Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/13/20257:00AMPR Newswire (US)Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/07/20259:20PMPR Newswire (US)Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/07/20257:00AMPR Newswire (US)Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/03/20254:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
12/20/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/09/20247:30AMPR Newswire (US)Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/07/20246:15PMPR Newswire (US)Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/06/20244:28PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
12/03/20244:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
11/27/20247:00AMPR Newswire (US)Syndax Announces Participation at the Citi 2024 Global Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/15/20245:29PMPR Newswire (US)Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/12/20247:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/12/20247:00AMPR Newswire (US)Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/05/20244:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
11/05/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/05/20244:01PMPR Newswire (US)Syndax Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/05/20249:01AMPR Newswire (US)Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
11/05/20249:00AMPR Newswire (US)Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/05/20249:00AMPR Newswire (US)Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/04/20244:01PMPR Newswire (US)Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™NASDAQ:SNDXSyndax Pharmaceuticals Inc
11/01/20244:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
11/01/20247:00AMPR Newswire (US)Syndax Announces Participation in November Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
10/29/20247:00AMPR Newswire (US)Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
10/21/20244:11PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
10/04/20244:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
09/18/20245:15PMPR Newswire (US)Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseaseNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/06/20244:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
08/15/20244:15PMBusiness WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
08/15/20246:26AMBusiness WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Your Recent History

USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
MONI
Moon Equity (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
AFFU
Affluence (PK)
NASDAQ
COOP
Mr Cooper
USOTC
CRTG
Coretec (QB)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
NLST
Netlist (QB)
USOTC
RDAR
Raadr (PK)
NASDAQ
ENTA
Enanta Pharmaceuticals
NASDAQ
TNXP
Tonix Pharmaceuticals
USOTC
AZRH
Azure (PK)
NASDAQ
NVDA
NVIDIA
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads